(NASDAQ: RLYB) Rallybio's forecast annual revenue growth rate of 479.55% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 35.42%, and it is also forecast to beat the US market's average forecast revenue growth rate of 9.66%.
Rallybio's revenue in 2024 is $299,000.On average, 2 Wall Street analysts forecast RLYB's revenue for 2024 to be $12,446,276, with the lowest RLYB revenue forecast at $12,446,276, and the highest RLYB revenue forecast at $12,446,276. On average, 1 Wall Street analysts forecast RLYB's revenue for 2027 to be $344,761,840, with the lowest RLYB revenue forecast at $344,761,840, and the highest RLYB revenue forecast at $344,761,840.
In 2028, RLYB is forecast to generate $2,800,826,931 in revenue, with the lowest revenue forecast at $2,800,826,931 and the highest revenue forecast at $2,800,826,931.